Recent news on Tysabri

EUROSHARES Lower after Wall Street retreat; OMX surges on Nasdaq ...  -  25 May 2007
Forbes,The broker said the current share price does not fully factor in the value of its Tysabri multiple sclerosis drug, which it markets in partnership with

Making sense of the biotech rumor mill  -  May 21, 2007
MSN MoneyThe majority of Biogen's sales comes from Avonex, a multiple sclerosis drug that competes with Tysabri. Last year, Biogen's impressive overall sales growth

Biogen Idec's Tysabri to be produced in Denmark  -  May 15, 2007
Milwaukee Business Journal,A California company will help Biogen Idec manufacture its multiple sclerosis drug Tysabri at a plant in Denmark. Jacobs Engineering Group (NYSE: JEC) said

Biogen Idec's Tysabri to be produced in Denmark  -  May 15, 2007
Bizjournals.com,Jacobs Engineering Group (NYSE: JEC) said Tuesday that Tysabri will be the first drug manufactured at the plant in Hillerod, Denmark.

Biogen upbeat on Tysabri progess  -  May 2, 2007
RTE.ie,Biotechnology company Biogen Idec, Elan's partner for developing the Tysabri drug, has reported first quarter profit of $132m, with sales of its MS

Biogen Idec: No new brain infections with Tysabri  -  May 3, 2007
Bizjournals.com,Biogen Idec said Thursday that there have been no new cases reported of a potentially fatal brain infection associated with its drug Tysabri since the

Biogen increases profit, warns of Tysabri costs  -  May 3, 2007
News & Observer,The company also announced progress in the launch of its next generation multiple sclerosis drug, Tysabri, but said expenses from the launch and clinical

Elan, Biogen say new data confirm safety profile of Tysabri  -  May 3, 2007
Forbes,Extension study data showed that Tysabri has a sustained treatment effect on clinical relapses and the risk of disability progression in multiple sclerosis

Wed: Teva just keeps going  -  May 14, 2007
Globes,Ever since it first faced the challenge from Tysabri in 2004, the damage caused to Teva's stock has often been quite severe and when Tysabri was approved,

Jacobs to Service Biogen Plant  -  May 15, 2007
Forbes,Biogen (nasdaq: BIIB - news - people ) will make multiple sclerosis treatment Tysabri at the plant, which is scheduled to be completed in 2009.

Biogen, Elan Get No New Reports  -  May 3, 2007
Wall Street JournalThe companies released the first safety update involving Tysabri since the drug was allowed back in the US market last June. The data was released at the

Jacobs receives contract for biotechnology project in Denmark  -  May 18, 2007
Construction and Maintenance News,The manufacturing facility is expected to produce TYSABRI (natalizumab), which is used in the treatment of multiple sclerosis. Officials did not disclose

NHS rationing of drugs condemned  -  May 12, 2007
Telegraph.co.uk,Among drugs rejected by Nice is Tysabri, which substantially reduces the chance of relapses in multiple sclerosis patients. One sufferer, Lesley Seddon,

Biogen Idec reports profit increase  -  May 2, 2007
MSN MoneyCEO James Mullen said in a statement that sales even grew steadily for multiple sclerosis drug Tysabri, which the US Food and Drug Administration reapproved

A Touch of Elan: Fool by Numbers  -  26 Apr 2007
Motley FoolRevenue grew by a whopping 31%, reflecting strong performance of Tysabri, as around 12500 patients have entered the TOUCH registration program with 9100

Doctors not prescribing meds that help MS patients  -  26 Apr 2007
Scientific AmericanThe first was Betaseron in 1993 and the most recent was Tysabri in 2006. Treatment with immunomodulatory agents, say the investigators, is thought to reduce

Elan drops 7pc on higher Q1 loss, Tysabri sales  -  Apr 24, 2007
Irish Independent,ELAN'S first quarter loss more than doubled and unspectacular sales from the performance of the company's multiple sclerosis treatment Tysabri following its

Tysabri reduces vision loss in recurring multiple sclerosis  -  Apr 18, 2007
Earthtimes.orgThe drug called natalizumab (brand name Tysabri) is commonly used in MS patients to reduce disability and to also slow down possible relapse.

Natalizumab (Tysabri) reduces vision loss in MS patients  -  Apr 18, 2007
News-Medical.net,...researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI), a drug that slows disability and reduces relapse

Natalizumab (Tysabri) Reduces Vision Loss in MS  -  Apr 17, 2007
MedPage Today,Note that these industry-sponsored studies suggests that the monoclonal antibody natalizumab (Tysabri) reduces the risk of clinically significant vision

Morning business - Apr 24  -  Apr 24, 2007
RTE.ie,ELAN'S TYSABRI NUMBERS UP 30% - Elan has just reported results for the first three months of the financial year. It reported increased losses, but revenues

Elan leans on ISEQ losers  -  Apr 24, 2007
Ireland Online,Shares at pharmaceutical company Elan tumbled 6% today after sales of its multiple sclerosis drug Tysabri came below expectations.

Tysabri - new option for multiple sclerosis  -  Apr 2, 2007
Healthcare RepublicBiogen Idec has launched Tysabri (natalizumab) as single disease modifying therapy in highly active relapsing-remitting multiple sclerosis for patients with

Elan Q1 loss seen widening despite sales rise  -  Apr 23, 2007
Therapeutics Daily (subscription) (press release),...on Tuesday thanks to new multiple sclerosis (MS) treatment Tysabri but the cost of the drug's re-launch will mean a widening in the company's loss.

MS drug fights vision loss  -  Apr 18, 2007
Health24.com,A controversial multiple sclerosis drug called Tysabri also reduces vision loss associated with the disease by 47 percent, a new study finds.

Reapproved drug leads the way for new treatments  -  Apr 3, 2007
Newsday,Finally, in January 2005 the Westbury resident received an infusion of the blockbuster drug Tysabri, which was pulled from the market during the month after

Mass. seeks documents from New Century Financial  -  Apr 17, 2007
Boston Globe,...s Tysabri drug, which slows disability and relapses of multiple sclerosis symptoms, also reduces vision loss in patients with the neurological disorder,

Drug reduces vision loss associated with relapsing multiple ...  -  Apr 17, 2007
OSN SuperSite (subscription),...double-blind, placebo-controlled, phase 3 trials involving 2138 patients with relapsing MS who were treated either with natalizumab (Tysabri,

Novartis Halts Zelnorm Sales  -  Apr 8, 2007
Chemical & Engineering NewsExamples include Pfizer's arthritis drug Bextra and Biogen Idec's multiple sclerosis drug Tysabri, both removed in 2005, and Merck's arthritis drug Vioxx,

New Oral Agents for Multiple Sclerosis, Including Novartis ...  -  Mar 29, 2007
Drug Newswire (press release),For safety concerns, Tysabri was pulled from shelves in 2005 -- following a safety review, the drug was re-approved by the Food and Drug Administration in

11am markets update  -  Apr 25, 2007
RTE.ie,...five cent at ¤10.35 after its pre-tax profits disappointed investors yesterday, although the company was upbeat on its Tysabri future performance.

FDA asks Novartis to halt sale of drug for bowel ills  -  Mar 30, 2007
Boston Globe,Last year, the FDA allowed Elan Corp. and Biogen Idec Inc.'s Tysabri multiple sclerosis medicine back on the market after the product was linked to a fatal

Daily Briefing  -  Apr 24, 2007
Atlanta Journal Constitution (subscription),PLC reported wider first-quarter losses alongside stronger sales Tuesday, and said its linchpin drug, the multiple-sclerosis-fighting Tysabri,

Amarin collapses as drug trials with Miraxion fail  -  Apr 24, 2007
Unison.ie (subscription),They added that the collapse was reminiscent of the slump in Elan shares when its multiple sclerosis treatment Tysabri had to be taken off the market.

Pipeline Insight: Multiple Sclerosis - The oral revolution  -  Mar 30, 2007
Pharmaceutical Business Review...(FTY720) goes some way to meet these needs and represents the most highly anticipated pipeline drug since the initial launch of Tysabri in 2004.

STOCK TALK: Aztrazeneca Buys Medimmune. Which Biotech Is Next?  -  Apr 23, 2007
Optionetics,The company’s products include cancer drug Rituxan and Tysabri for multiple sclerosis. It is viewed as a takeover play because it has many of the same

MS Patients Not Receiving Medications To Slow Disease Progression ...  -  Apr 20, 2007
Medical News Today (press release),...interferon-1a (Avonex®), glatiramer acetate (GA or Copaxone®), interferon-1a (Rebif®), mitoxantrone (Novantrone®) and natalizumab (Tysabri®).

Treatment For MS Patients Also Reduces Their Vision Loss, Penn ...  -  Apr 20, 2007
Medical News Today (press release),According to a study that appears in Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI®) - a

Japan drug industry indulges yen for biotech  -  Apr 19, 2007
International Herald Tribune,Biogen Idec's Tysabri costs $28400 a year. Products of US biotechnology companies accounted for $40.3 billion, or 15 percent, of drug purchases last year,

Takeda, Eisai Raise Biotech Costs for Merck, Novartis (Update2)  -  Apr 19, 2007
BloombergBiogen Idec Inc.'s Tysabri costs $28400 a year. Products of US biotechnology companies accounted for $40.3 billion, or 15 percent, of drug purchases last

Why I Bought Covance (Again)  -  Apr 19, 2007
Seeking Alpha,With Vioxx, Tysabri and so many other issues recently, there is increasing need (and probable political intervention) to study long-term safety,

Financially Set or Seriously Rich?  -  Apr 18, 2007
Motley FoolLikewise, many investors recently recognized that Elan's chances of getting its multiple-sclerosis drug Tysabri back were much higher than the market had

MS patients not receiving medications to slow disease progression  -  Apr 18, 2007
News-Medical.net,...interferon-1a (Avonex), glatiramer acetate (GA or Copaxone), interferon-1a (Rebif), mitoxantrone (Novantrone) and natalizumab (Tysabri).

Penn researchers find treatment for MS also reduces vision loss in ...  -  Apr 17, 2007
SpiritIndia,...researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI®) – a drug that slows disability and reduces

Novartis Gets Nicked  -  Apr 4, 2007
Motley FoolThe most publicized drug withdrawals happened in late 2004 with Merck's (NYSE: MRK) arthritis and pain drug Vioxx, and in early 2005 with Tysabri,

Teenager gets radical MS drug on NHS  -  27 Mar 2007
Scotsman,The 16-year-old, from Gullane, has successfully applied to NHS Lothian to use Tysabri, at a cost of £15000 a year, despite a ruling by drugs officials that

NICE appraises multiple sclerosis drug Tysabri  -  Mar 5, 2007
SpiritIndia,The NICE appraisal committee meets to assess Tysabri today (6 March). Amongst the people making representations are two people personally affected by MS

Harry Potter author blasts Tysabri ban  -  Feb 28, 2007
United Press InternationalThe Scottish Medicines Consortium in December advised against the use of Tysabri on economic grounds. The Scottish Parliament is slated to hold a debate on

Multiple Sclerosis Affects Less Than 1% Of The Population In The ...  -  Mar 22, 2007
PharmaLive.com (press release),Tysabri, a novel once-monthly drug is expected to be an improvement in terms of efficacy; however, there remains a concern over side effects and long-term

Voice of the Reader 3-15  -  Mar 15, 2007
The Southern,Using Tysabri for MS is anything but dangerous: To the Editor: Since March is Multiple Sclerosis Education and Awareness Month, I felt compelled to write

Multiple sclerosis drug brings lethal risks, but great promise for ...  -  Mar 9, 2007
Kansas City Star,After a horrible year of MS relapses in 2006, she reckons that the same drug, Tysabri, will reduce the odds of another setback from which she might not

Dueling Fools: Elan Bear Rebuttal  -  Mar 15, 2007
Motley FoolI could write a book on the relative efficacy and safety of Tysabri versus the other MS CRAB treatments (enterprising investors can start by comparing the

Dueling Fools: Elan Bear  -  Mar 15, 2007
Motley FoolElan is best known nowadays for its multiple sclerosis treatment Tysabri and the saga of bringing it to market. Elan and marketing partner Biogen IDEC

Needed From the FDA: Not Perfection, Just Consistency  -  Mar 8, 2007
TCS Daily,In recent decisions on the post-approval risk management of two drugs, Tysabri and Rituxan, FDA regulators have failed to be internally consistent - and

Multiple sclerosis drug brings lethal risks, but great promise for ...  -  Mar 3, 2007
Milwaukee Journal Sentinel (subscription),Krista Chapman receives her first infusion of Tysabri, from nurse Chris Vickerman, at Waukesha Memorial Hospital recently.

Dueling Fools: Elan Bull  -  Mar 15, 2007
Motley FoolYou may have heard of this promising little drug called Tysabri. Clinical trials and nearly a year of real-world sales and treatments have so far agreed

Wonder Drug To Be Blocked  -  Mar 17, 2007
Sky News,Tysabri is a monoclonal antibody that has also proven to be beneficial in treating Crohn's disease, which, like MS, is also an autoimmune disorder.

Dueling Fools: Elan Bull Rebuttal  -  Mar 15, 2007
Motley FoolHe thinks multiple sclerosis drug Tysabri is too risky and not profitable enough to support the current valuation, but I'm convinced otherwise for a couple

McGrigor call for MS drug to be put on NHS  -  Mar 9, 2007
Shetland Times,However, the SMC's decision not to recommend Tysabri for use in the NHS has come as a bitter blow to patients with the most aggressive form of the disease,

Rowling hits out at NHS ban on costly MS treatment for Scots  -  Feb 27, 2007
Scotsman,The Harry Potter author, whose mother suffered MS, broke her silence on the Scottish Medicines Consortium's refusal to recommend Tysabri ahead of a debate

Dual Buffett Strategy  -  Mar 5, 2007
Forbes,In 2005, the company pulled its multiple sclerosis drug, Tysabri, from the market after a patient who was taking the drug in conjunction with another

Gurus Buy Banks, Prep For Inflation  -  Mar 13, 2007
Forbes,The M100 sold most of their shares of the company, which they’ve been in and out of for years while the soap opera-esque Tysabri saga has played out for it

PDL's Friend Comes Through  -  Mar 16, 2007
Motley FoolBiogen and partner Elan (NYSE: ELN) learned that two years ago, with Tysabri running into trouble in combination therapy. Just as PDL deserves blame for its

"Multiple Sclerosis: The Latest Findings"  -  Mar 9, 2007
Garden City News,Sharon-Friedman Urevich, RN, NP, Coordinator of Winthrop's MS Program; Eileen Boylan, RN, and Denise Cheng, RN, will the practical aspect of Tysabri(r),

Dueling Fools: Elan  -  Mar 15, 2007
Motley FoolAnd of course, when I say Elan, I'm pretty much boiling it down to its Tysabri drug. A lot of the Irish drug maker's future is banking on the success of its

Inflammatory bowel disease: new treatments won't set market alight  -  Feb 28, 2007
Pharmaceutical Business ReviewIn particular, Elan and Biogen Idec's resurrected Tysabri (natalizumab) will provide a promising candidate for patients failing anti-TNF,

ROWLING CALLS FOR MS DRUG RETHINK  -  Feb 28, 2007
Glasgow Daily Record,The Harry Potter author called on the Scottish Medicines Consortium to rethink their decision not to approve Tysabri for multiple sclerosis sufferers on the

JK Rowling Condemns MS Drug Ban Ahead of Holyrood Debate  -  Feb 28, 2007
Nieuwsbank (abonnement),The Scottish Medicines Consortium (SMC) advised against the use of Tysabri - a drug for people affected by severe relapsing remitting multiple sclerosis

Elan "add"  -  Mar 9, 2007
newratings.com...rather than the previous estimate of profits of $7.4 million due to the pullback of revenue estimates for Tysabri and higher cost estimates.

FDA would limit input of doctors paid by drug firms  -  Mar 22, 2007
Boston Globe,For instance, in 2006, a FDA panel unanimously agreed to allow renewed sales of Tysabri, a multiple sclerosis treatment comarketed by Biogen Idec Inc. of

Market Report -- Short Stories (BIIB)  -  Mar 6, 2007
MSN MoneyThe firm says the difficult hurdles of the last couple of years are now past and ramp-up in sales of Tysabri has been evident.

Rough Week for Biotech  -  Mar 5, 2007
Seeking Alpha,It was even more negative than the week in early 2005 when Tysabri was pulled from the market, a week that saw only a 4.5% drop.

MSPs debate ruling to deny MS drug on NHS  -  Mar 1, 2007
Scotsman,The Scottish Medicines Consortium (SMC) has advised on economic grounds against the use of Tysabri, which is a drug for people affected by severe MS.

Santa Clarita Calendar  -  Mar 25, 2007
Los Angeles Daily News,He will talk about Tysabri, the latest drug treatment for MS as well as answering other MS-related questions. Brandes is an assistant clinical professor at

Financially Set or Seriously Rich?  -  Mar 22, 2007
Motley FoolLikewise, many investors recently recognized that Elan's chances of getting its multiple-sclerosis drug Tysabri back were much higher than the market had

Biogen tunes up in RTP as drugs display promise  -  Mar 2, 2007
Triangle Business Journal,Biogen Idec currently manufactures bulk drugs Avonex and Tysabri at the site. Avonex, a treatment for multiple sclerosis, generated 2006 sales of $1.7

Voice of the Reader 3-21  -  Mar 21, 2007
The Southern,Although there are several effective and beneficial treatment choices on the market, the addition of Tysabri has been a tremendous, positive step.

Investing in Your Backyard: Ireland  -  Mar 17, 2007
MSNBC..."Elan is way more than MS and Tysabri. While that drug will drive sales, profits, and stock price increases for a good handful of years, the more important

Teva Receives First US Approval For Generic UNIRETIC(R) Tablets  -  Mar 12, 2007
PipelineReview.com (press release),Neurontin®, Oxycontin® and Zithromax®, the effects of competition on Copaxone® sales, including as a result of the expected reintroduction of Tysabri®

WEEKLY ROUND-UP : Dublin shakes off recent nerves and regains its ...  -  Mar 9, 2007
Irish Independent,...firm Elan saw a further 3pc wiped off their share values, as the market tires with less than encouraging news on the firm's MS drug Tysabri.

Analysis: Hollis-Eden to endure stock nuke  -  Mar 8, 2007
Science Daily (press release)Analysis: Street eyeing Biogen's Tysabri (February 15, 2007) -- Biogen Idec's fourth quarter net income more than doubled, but the company's earnings fell

Former surfer wants to spread the word on multiple sclerosis  -  Mar 9, 2007
Ventura County Star (subscription),She attends a Camarillo support group and keeps a blog where she writes about MS and her experience with a new drug treatment called Tysabri.

The Wonder Drug  -  Mar 5, 2007
Carthage Press,The USDA approved a new drug called "Tysabri" for the treatment of multiple sclerosis that affects 350000 Americans. The cost of the drug is guesstimated to

Living with MS  -  Mar 4, 2007
Gainesville Times,Still, he's eager to try Tysabri, a drug that shows promising results for some people but has been restricted by the FDA because of a potentially lethal

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional